Orexo Stakes Out $500M Market for New Opioid-Addiction Drug
Orexo stakes out 0M market for new opioid-addiction drug
The Swedish specialty pharma outfit has been given the green light to start marketing the sublingual Zubsolv, a combination of buprenorphine and naloxone for use in treating withdrawal symptoms from heroin and opioid pain killers. Shares of Orexo shot …
Read more on FierceBiotech